June 24, 2005
FDA Statement on Guidant Corporation’s Worldwide
Physician Communications
"The FDA is pleased that Guidant Corporation is communicating
important safety information to the public regarding
their implantable defibrillators," said Dr. Daniel Schultz,
FDA Director of the Center for Devices and Radiological
Health. "The Agency continues to work with the company
on this public health issue and encourages patients to
talk with their physicians about their Guidant device.
As more information becomes available on the devices
impacted (CONTAK RENEWAL 3 and 4, RENEWAL 3 and 4 AVT,
and RENEWAL RF), the FDA will share it quickly with the
public."
Read the complete statement at: http://www.fda.gov/bbs/topics/NEWS/2005/NEW01192.html
Guidant
Corporation issues medical safety information
and corrective action. 